Aptinyx Inc.: insider trades · United States · SEC (Form 4)

About Aptinyx Inc.

Aptinyx Inc. (ticker: APTX) is a U.S.-based biopharmaceutical company that was historically listed on the NASDAQ in the United States. The company was founded in 2015 in Delaware and was headquartered in Evanston, Illinois. Aptinyx was built as a clinical-stage CNS-focused biotech, with a research platform centered on proprietary synthetic small molecules designed to modulate NMDA receptors, a biological pathway involved in brain and nervous-system function. In other words, the company’s business model was not broad-based commercial pharma, but a targeted drug-development platform aimed at discovering and advancing therapies for disorders of the brain and nervous system. Aptinyx’s main programs included NYX-783, NYX-458, and NYX-2925. These assets were developed for indications such as opioid use disorder, cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies, and chronic pain. The company’s pipeline reflected a classic venture-backed biotech strategy: concentrate capital on a small number of differentiated candidates, generate clinical proof-of-concept, and then move toward larger-scale development or partnering. However, the recent clinical record proved challenging. Aptinyx discontinued NYX-2925 after two Phase 2b studies in chronic pain failed to show sufficient efficacy, later stopped NYX-458 after a Phase 2 study did not produce clinically meaningful benefit, and then discontinued NYX-783 in PTSD after an early termination analysis showed insufficient improvement on the primary endpoint. Those setbacks materially weakened the investment case. The most important recent corporate event was strategic rather than operational: on June 30, 2023, stockholders approved the company’s liquidation and dissolution, and Aptinyx filed a certificate of dissolution with the Delaware Secretary of State on July 5, 2023. Nasdaq subsequently announced the delisting of Aptinyx common stock; the securities had been suspended on May 19, 2023 and had not traded on Nasdaq since that date. As a result, APTX should now be viewed as a wind-down situation rather than an ongoing listed growth biotech. From a competitive standpoint, Aptinyx operated in the highly crowded CNS drug-development space, where scientific differentiation is necessary but not sufficient. The company’s NMDA-focused platform was intellectually distinctive, but clinical execution did not deliver durable value creation. For investors, the relevant issues are now limited to liquidation mechanics, any residual asset value, and SEC disclosures such as Form 4 insider transactions, if applicable. In practical terms, Aptinyx is no longer a normal listed operating company; it is a dissolved U.S. biotech with historical NASDAQ exposure and a legacy pipeline that has largely been shut down.